CoChat

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Purpose: Nintedanib enhances the activity of chemotherapy in metastatic non–small cell lung cancer (NSCLC). In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint. Patients and Methods: Eligible patients had stage IB (≥4 cm)–IIIA resectable NSCLC. A safety run-in phase was followed by an expansion phase with nintedanib 200 mg orally twice a day (28 days), followed by three cycles of cisplatin (75 mg/m2), docetaxel (75 mg/m2) every 21 days plus nintedanib, followed by surgery. With 33 planned patients, the study had 90% power to detect an MPR increase from 15% to 35%. Results: Twenty-one patients (stages I/II/III, N = 1/8/12) were treated. One of 15 patients treated with nintedanib 200 mg achieved MPR [7%, 95% confidence interval (CI), 0.2%–32%]. Best ORR in 20 evaluable patients was 30% (6/20, 95% CI, 12%–54%). Twelve-month recurrence-free survival and overall survival were 66% (95% CI, 47%–93%) and 91% (95% CI, 79%–100%), respectively. Most frequent treatment-related grade 3–4 toxicities were transaminitis and electrolyte abnormalities. On the basis of an interim analysis the study was discontinued for futility. Higher levels of CD3+ and cytotoxic CD3+CD8+ T cells were found in treated tumors of patients who were alive than in those who died (652.8 vs. 213.4 cells/mm2, P = 0.048; 142.3 vs. 35.6 cells/mm2, P = 0.018). Conclusions: Although tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies. See related commentary by Blakely and McCoach, p. 3499

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-4180

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 31

Metadata

Authors
Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., Lam, V. K., Lu, C., Mott, F. E., Simon, G. R., Antonoff, M. B., Mehran, R. J., Rice, D. C., Behrens, C., Weissferdt, A., Moran, C., Vaporciyan, A. A., Lee, J. J., Swisher, S. G., Gibbons, D. L., Wistuba, I. I., William, W. N., & Heymach, J. V.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • 4Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Corresponding author
  • William, William N.
  • Heymach, John V.
Venue
Clinical Cancer Research
Published
2020-07-15
Volume
26
Issue
14
Pages
3525-3536
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3011014692
Cited by
31
References
35
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 1
FWCI
3.10
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Boehringer Ingelheim
  • Lung SPORE grant 5 (P50 CA070907)
  • Cancer Center Support Grant (P30 CA016672)
  • American Society of Clinical Oncology (12895)
  • The University of Texas MD Anderson Cancer Center Lung Cancer Moon Shot Program
  • The University of Texas MD Anderson Cancer Center CG Johnson Foundation Advanced Scholar Program
  • The University of Texas MD Anderson Cancer Center Khalifa Scholar Program
  • The University of Texas MD Anderson Cancer Center Physician Scientist Program
  • T.J. Martell Foundation
  • Bruton Endowed Chair in Tumor Biology Funds
  • The Bob Mayberry Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
nintedanib, non-small cell lung cancer, neoadjuvant chemotherapy, cisplatin, docetaxel, resectable lung cancer, major pathological response, tumor-infiltrating lymphocytes, CD8+ T cells, treatment toxicity, futility, recurrence-free survival, overall survival, tyrosine kinase inhibitor combination therapy, immunotherapy biomarkers, elevated liver enzymes
MeSH terms
Docetaxel, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Humans, Indoles, Lung Neoplasms, Neoplasm Staging, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-4180
The paper
Cascone, T., Sepesi, B., Lin, H. Y., Kalhor, N., Parra, E. R., Jiang, M., Godoy, M. C. B., Zhang, J., Fossella, F. V., Tsao, A. S., Lam, V. K., Lu, C., Mott, F. E., Simon, G. R., Antonoff, M. B., Mehran, R. J., Rice, D. C., Behrens, C., Weissferdt, A., . . . Heymach, J. V. (2020). A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-4180

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.